Le marché des injectables génériques devrait atteindre 150,65 milliards de dollars américains d'ici 2028, contre 74,74 milliards de dollars américains en 2021 ; il devrait enregistrer un TCAC de 10,5 % de 2021 à 2028.
Les injectables génériques sont les bioéquivalents de leurs homologues de marque et ne sont pas protégés par des brevets. Ils sont sûrs et efficaces en tant que médicaments innovants car ils ont des ingrédients actifs, des dosages, une force, des qualités, une forme, etc. similaires. Le rapport offre des informations et une analyse approfondie du marché des injectables génériques, en mettant l'accent sur divers paramètres tels que les tendances du marché, la technologie les progrès et la dynamique du marché ; il fournit également l'analyse du paysage concurrentiel des principaux acteurs du marché et l'impact de la pandémie de COVID-19 sur le marché dans toutes les grandes régions. La pandémie de COVID-19 a perturbé les conditions socio-économiques de divers pays à travers le monde. Selon les récentes statistiques de l'OMS, les États-Unis sont le pays le plus touché au monde en raison de la pandémie avec le plus grand nombre de cas. Le nombre élevé de cas de COVID a eu un impact négatif sur l'économie des États-Unis et, par conséquent, sur celle de l'Amérique du Nord. Il y a eu une baisse des activités commerciales globales et une croissance de diverses industries opérant dans la région.
Perspectives stratégiques
Cependant, il était une demande inhabituelle de Remdesivir, un médicament antiviral utilisé pour traiter les patients, lorsque l'épidémie était à son apogée. Ainsi, les fabricants du marché des injectables génériques sont désormais préparés pour l'avenir car ils se concentrent sur le maintien d'un stock adéquat pour que les opérations de la chaîne d'approvisionnement ne soient pas affectées par tout type de vulnérabilité. Gilead Sciences et d'autres grandes sociétés pharmaceutiques, par exemple, ont considérablement réduit les prix de leurs versions génériques du remdesivir. Les entreprises utilisent les programmes gouvernementaux et les plans de financement proposés par les industries BFSI pour rationaliser leurs opérations. En mai 2020, le gouvernement américain a conclu un accord d'une valeur de 812 millions de dollars américains avec un groupe de fabricants américains de médicaments génériques, dans le but de renforcer l'approvisionnement en médicaments du pays dans le contexte de la pandémie mondiale de COVID-19. industries à l'échelle mondiale, interrompant et retardant l'approvisionnement de divers médicaments essentiels. De nombreux acteurs du marché sont venus à la rescousse avec des actions immédiates. Par exemple, en janvier 2021, Civica Rx s'est associée à la toute nouvelle Phlow Corp. dans le but de soutenir la fabrication de médicaments aux États-Unis et de fournir des médicaments essentiels aux hôpitaux qui luttent contre la pandémie. Civica a investi 124,5 millions de dollars américains dans la construction d'une usine de fabrication d'injectables stériles à Petersburg, en Virginie, qui a pris de l'importance l'année dernière grâce à un important contrat gouvernemental pour la production de médicaments liés au COVID-19. Selon la région, le marché des injectables génériques est segmenté en Amérique du Nord, Europe, Asie-Pacifique, Moyen-Orient et Afrique, et Amérique du Sud et centrale.
Régions lucratives pour le marché des injectables génériques
Market Insights La forte demande de médicaments abordables stimule le marché des injectables génériques
Les médicaments innovants sont chers en raison des investissements importants réalisés dans la recherche et le développement de molécules ; ces médicaments sont particulièrement inabordables pour une grande partie de la population des pays en développement. Cependant, les médicaments génériques sont abordables et offrent un meilleur accès aux soins de santé. Comme publié par l'Association for Accessible Medicines (AAM), la quote-part primaire moyenne (le montant fixé par les régimes d'assurance) d'un médicament générique est de 6,06 USD et de 40,30 USD pour les médicaments de marque. Ce fait indique la baisse des prix des médicaments génériques d'au moins ~ 7 %. Selon l'American Association of Retired Person (AARP), les prix des médicaments de marque continuent d'augmenter à un rythme 100 fois supérieur à l'inflation. De plus, comme mentionné par l'USFDA, 9 ordonnances sur 10 remplies aux États-Unis concernent des médicaments génériques. De plus, les prix moyens des fabricants de médicaments génériques (AMP) sont inférieurs d'environ 39 % à ceux des médicaments de marque AMP. Par exemple, tel que publié par l'Association for Accessible Medicines (AAM), 93 % des ordonnances génériques sont remplies pour 20 $ US ou moins. Les faits mentionnés ci-dessus stimulent la demande et la disponibilité des injectables génériques, entraînant ainsi l'entrée d'un plus grand nombre d'acteurs sur le marché des injectables génériques. De plus, les bas prix des injectables génériques contribuent à des traitements plus efficaces et plus efficaces contre les maladies chroniques. Selon l'Organisation mondiale de la santé (OMS), environ 422 millions de personnes dans le monde étaient diabétiques en 2021. Les injectables génériques tels que les injections d'insuline offrent des solutions immédiates à ces affections, tout en garantissant des traitements abordables dans les pays en développement.
Informations basées sur le type de produit
En fonction du type de produit, le marché des injectables génériques est segmenté en injectables à grandes molécules et injectables à petites molécules. En 2021, le segment des injectables à grosses molécules représentait une plus grande part de marché. La position de marché de ce segment est attribuée à une augmentation de l'adoption de produits biologiques dans le secteur de la santé et à la progression des anticorps monoclonaux et des conjugués anticorps-médicament (ADC) dans le développement de médicaments.
Marché des injectables génériques, par type de produit - 2020 et 2028
Insights basés sur le type de conteneur
< CONSEIL>
En fonction du type de conteneur, le marché des injectables génériques est segmenté en flacons, prémélanges, seringues préremplies, ampoules et autres. Le segment des flacons devrait dominer le marché en 2021.
Application-Based Insights
Le marché des injectables génériques, basé sur l'application , a été classé en oncologie, maladies infectieuses, cardiologie, diabète, immunologie et autres. Le segment de l'oncologie devrait détenir la plus grande part du marché en 2021. Une augmentation de l'incidence du cancer et une augmentation du lancement de médicaments devraient stimuler la croissance du segment de marché de l'oncologie.
< h3>Voie d'informations basées sur l'administration
Sur la base de la voie d'administration, le marché des injectables génériques a été classé en intraveineux, intramusculaire, sous-cutané et autres. Le segment intraveineux détenait la plus grande part de marché en 2021. Les acteurs du marché des injectables génériques adoptent des stratégies organiques telles que le lancement et l'expansion de produits pour étendre leur empreinte et leur portefeuille de produits dans le monde entier.
Par géographie
Amérique du Nord
< TIP>- États-Unis
- Canada
- Mexique
Europe
- France
- Allemagne< /li>
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe < TIP>
Asie-Pacifique (APAC)
< li>Chine- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
Moyen-Orient et Afrique (MEA )
- Afrique du Sud
- Arabie saoudite
- EAU < TIP>
- Reste de MEA
Amérique du Sud et centrale (SCAM)
- Brésil
- Argentine
- Reste de l'arnaque
< /ol>
< /ol>
Profils d'entreprise
- Astrazeneca
- Baxter International, Inc.
- Biocon
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Merck & Co., Inc.
- Mylan NV
- Pfizer, Inc
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Generic Injectables are safe and effective innovator bio-equivalent drugs of their branded counterparts which are not protected by drug patents. They have a similar ingredient, dosage, strength, quality, form, etc.
High demand for affordable drugs is one of the most significant factors responsible for the overall market growth.
Based on product type, large molecule injectables took the forefront leaders in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The oncology segment dominated the global generic injectables market and accounted for the largest revenue of 21.62 Bn in 2021.
Astrazeneca, Baxter International, Inc., Biocon, Fresenius SE & Co., KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin, Ltd., Merck & Co., Inc., Mylan N.V., Pfizer, Inc. are among the leading companies operating in the global generic injectables market
Global generic injectables market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for generic injectables market. The US is estimated to hold the largest share in the generic injectables market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for generic injectables accounting fastest growth of the region during the coming years.
The List of Companies - Generic Injectables Market
- Astrazeneca
- Baxter International, Inc.
- Biocon
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Pfizer, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)